Characterization of Reproductive, Metabolic, and Endocrine Features of Polycystic Ovary Syndrome in Female Hyperandrogenic Mouse Models

被引:251
作者
Caldwell, A. S. L. [1 ]
Middleton, L. J. [1 ]
Jimenez, M. [1 ]
Desai, R. [1 ]
McMahon, A. C. [2 ]
Allan, C. M. [1 ]
Handelsman, D. J. [1 ]
Walters, K. A. [1 ]
机构
[1] Univ Sydney, ANZAC Res Inst, Androl Lab, Sydney, NSW 2139, Australia
[2] Univ Sydney, ANZAC Res Inst, Biogerontol Lab, Sydney, NSW 2139, Australia
基金
澳大利亚研究理事会; 英国医学研究理事会;
关键词
FOLLICLE-STIMULATING-HORMONE; PRENATAL TESTOSTERONE; ANDROGEN EXCESS; SYNDROME PCOS; TARGETED DISRUPTION; LUTEINIZING-HORMONE; RHESUS-MONKEYS; CYCLING RATS; MICE; DEHYDROEPIANDROSTERONE;
D O I
10.1210/en.2014-1196
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Polycystic ovary syndrome (PCOS) affects 5-10% of women of reproductive age, causing a range of reproductive, metabolic and endocrine defects including anovulation, infertility, hyperandrogenism, obesity, hyperinsulinism, and an increased risk of type 2 diabetes and cardiovascular disease. Hyperandrogenism is the most consistent feature of PCOS, but its etiology remains unknown, and ethical and logistic constraints limit definitive experimentation in humans to determine mechanisms involved. In this study, we provide the first comprehensive characterization of reproductive, endocrine, and metabolic PCOS traits in 4 distinct murine models of hyperandrogenism, comprising prenatal dihydrotestosterone (DHT, potent nonaromatizable androgen) treatment during days 16-18 of gestation, or long-term treatment (90 days from 21 days of age) with DHT, dehydroepiandrosterone (DHEA), or letrozole (aromatase inhibitor). Prenatal DHT-treated mature mice exhibited irregular estrous cycles, oligo-ovulation, reduced preantral follicle health, hepatic steatosis, and adipocyte hypertrophy, but lacked overall changes in body-fat composition. Long-term DHT treatment induced polycystic ovaries displaying unhealthy antral follicles (degenerate oocyte and/or > 10% pyknotic granulosa cells), as well as anovulation and acyclicity in mature (16-week-old) females. Long-term DHT also increased body and fat pad weights and induced adipocyte hypertrophy and hypercholesterolemia. Long-term letrozole-treated mice exhibited absent or irregular cycles, oligo-ovulation, polycystic ovaries containing hemorrhagic cysts atypical of PCOS, and displayed no metabolic features of PCOS. Long-term dehydroepiandrosterone treatment produced no PCOS features in mature mice. Our findings reveal that long-term DHT treatment replicated a breadth of ovarian, endocrine, and metabolic features of human PCOS and provides the best mouse model for experimental studies of PCOS pathogenesis.
引用
收藏
页码:3146 / 3159
页数:14
相关论文
共 65 条
  • [1] Contributions of androgen and estrogen to fetal programming of ovarian dysfunction
    Abbott, David H.
    Padmanabhan, Vasantha
    Dumesic, Daniel A.
    [J]. REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, 2006, 4 (1)
  • [2] Nonhuman primate models of polycystic ovary syndrome
    Abbott, David H.
    Nicol, Lindsey E.
    Levine, Jon E.
    Xu, Ning
    Goodarzi, Mark O.
    Dumesic, Daniel A.
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2013, 373 (1-2) : 21 - 28
  • [3] Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome?
    Abbott, DH
    Barnett, DK
    Bruns, CM
    Dumesic, DA
    [J]. HUMAN REPRODUCTION UPDATE, 2005, 11 (04) : 357 - 374
  • [4] Insights into the development of polycystic ovary syndrome (PCOS) from studies of prenatally androgenized female rhesus monkeys
    Abbott, DH
    Dumesic, DA
    Eisner, JR
    Colman, RJ
    Kemnitz, JW
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1998, 9 (02) : 62 - 67
  • [5] Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline
    Azziz, Ricardo
    Carmina, Enrico
    Dewailly, Didier
    Diamanti-Kandarakis, Evanthia
    Escobar-Morreale, Hector F.
    Futterweit, Walter
    Janssen, Onno E.
    Legro, Richard S.
    Norman, Robert J.
    Taylor, Ann E.
    Witchel, Selma F.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (11) : 4237 - 4245
  • [6] The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report
    Azziz, Ricardo
    Carmina, Enrico
    Dewailly, Didier
    Diamanti-Kandarakis, Evanthia
    Escobar-Morreale, Hector F.
    Futterweit, Walter
    Janssen, Onno E.
    Legro, Richard S.
    Norman, Robert J.
    Taylor, Ann E.
    Witchel, Selina F.
    [J]. FERTILITY AND STERILITY, 2009, 91 (02) : 456 - 488
  • [7] Adipocyte biology in polycystic ovary syndrome
    Barber, T. M.
    Franks, S.
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2013, 373 (1-2) : 68 - 76
  • [8] Beloosesky R, 2004, INT J MOL MED, V14, P207
  • [9] Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism
    Brennan-Speranza, Tara C.
    Henneicke, Holger
    Gasparini, Sylvia J.
    Blankenstein, Katharina I.
    Heinevetter, Uta
    Cogger, Victoria C.
    Svistounov, Dmitri
    Zhang, Yaqing
    Cooney, Gregory J.
    Buttgereit, Frank
    Dunstan, Colin R.
    Gundberg, Caren
    Zhou, Hong
    Seibel, Markus J.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (11) : 4172 - 4189
  • [10] An age-related ovarian phenotype in mice with targeted disruption of the Cyp 19 (aromatase) gene
    Britt, KL
    Drummond, AE
    Cox, VA
    Dyson, M
    Wreford, NG
    Jones, MEE
    Simpson, ER
    Findlay, JK
    [J]. ENDOCRINOLOGY, 2000, 141 (07) : 2614 - 2623